Patients with a history of venous thrombotic episodes such as deep venous thrombosis, pulmonary embolus occurring more than 6 months prior to enrollment may be considered for protocol participation, provided they are on stable doses of anticoagulant therapy; similarly, patients who are anticoagulated for atrial fibrillation or other conditions may participate, provided they are on stable doses of anticoagulant therapy
Subjects with a history of venous thrombosis within the past 3 months
Patients with a history of deep vein thrombosis, pulmonary embolism, or any other significant thromboembolism (venous port or catheter thrombosis or superficial venous thrombosis are not considered “significant”) during the 3 months prior to registration
History of unprovoked venous thrombosis/thromboembolism
History of venous thromboembolism (e.g. deep venous thrombosis or pulmonary embolism) within 6 months of study entry; Note: participants enrolled after this window must be on appropriate therapeutic anticoagulation
History of deep vein thrombosis, pulmonary embolism, or any other significant thromboembolism (venous port of catheter thrombosis or superficial venous thrombosis are not considered “significant”) during the 3 months prior to enrollment
Active venous thrombosis with contraindication for anticoagulation
Requirement of therapeutic anticoagulant therapy with oral vitamin K antagonists; low-dose anticoagulants for maintenance of patency of central venous access devise or prevention of deep venous thrombosis is allowed; therapeutic use of low molecular weight heparin (or similar parenteral drug) for venous-thromboembolic disease is allowed
Patients determined to be at increased risk of arterial or venous thrombosis by the investigator
History of deep venous thrombosis, clinically significant peripheral vascular disease, or other thrombotic event
Has a history of arterial thromboembolism within 12 months of start of study drug
Internal jugular venous thrombosis, acute or within 3 months.
Any history of venous or arterial thromboembolism including deep venous thrombosis or pulmonary embolism. Patients with a history of treated prior superficial or catheter associated will not be considered as significant embolism and after discussion with principal investigator (PI) will not be excluded from eligibility. Uncontrolled hypertension (diastolic blood pressure > 90 mmHg; systolic > 140 mmHg). Patients with hypertension should be under treatment on study entry to effect blood pressure control.
Subject has a history of non-central line related thrombosis (arterial or venous), more than one prior central-line related thrombosis or known coagulopathy.
PONATINIB \r\n* Patients with cytogenetically ‘favorable risk' AML (core-binding factor leukemias) will not be enrolled on the ponatinib arm; testing with cytogenetics and fluorescence in situ hybridization (FISH) can establish this subtype within 7 days of the diagnostic bone marrow biopsy\r\n* History of acute pancreatitis within 1 year of study or history of chronic pancreatitis\r\n* Uncontrolled hypertriglyceridemia (triglycerides > 450 mg/dL)\r\n* Any history of myocardial infarction, stroke, or revascularization\r\n** Any history of venous thromboembolism including deep venous thrombosis or pulmonary embolism with the exception of upper Extremity/Line associated deep vein thrombosis (DVTs) which are adequately treated (line removed and/or patient anti-coagulated)\r\n* Uncontrolled hypertension (diastolic blood pressure > 90 mm Hg; systolic > 140 mm Hg); patients with hypertension should be under treatment on study entry to effect blood pressure control
Patients with history of bleeding diathesis, arterial thromboembolism, current use of therapeutic anticoagulation with oral vitamin K antagonists, factor Xa inhibitors, heparin products, oral direct thrombin inhibitors, or presence of non-healing wounds; low-dose anticoagulants for maintenance of patency of central venous access device or prevention of deep venous thrombosis is allowed
The patient has a history of deep vein thrombosis, pulmonary embolism, or any other significant thromboembolism (venous port or catheter thrombosis or superficial venous thrombosis are not considered “significant”) during the 3 months prior to randomization
History of arterial thrombosis within 3 months of starting study treatment
The patient has a history of deep vein thrombosis, pulmonary embolism, or any other significant thromboembolism, including portal venous thrombosis (venous port or catheter thrombosis, incidental pulmonary embolism diagnosed on imaging studies or superficial venous thrombosis are not considered significant) during the 3 months prior to randomization
Has had a symptomatic venous thrombosis within 2 weeks prior to study enrollment - NOTE: Subjects with a history of a deep vein thrombosis >2 weeks prior to study enrollment who are on anticoagulation therapy with low molecular weight heparin are eligible for this study
Venous thromboembolism, including deep venous thrombosis or pulmonary embolism, within 6 months prior to enrollment
Patients with history of recurrent venous thromboembolism (deep venous thrombosis or pulmonary embolism) or history of venous thromboembolism within 6 months prior to registration on study will not be eligible
History of deep vein thrombosis, pulmonary embolism, or any other significant thromboembolism (venous port or catheter thrombosis or superficial venous thrombosis are not considered “significant”) during the 3 months prior to randomization
Patients must not have been previously diagnosed with a deep venous or arterial thrombosis (including pulmonary embolism), and must not have a known thrombophilic condition
MATCHED RELATED DONOR: Other medical contraindications to stem cell donation (i.e. severe atherosclerosis, autoimmune disease, iritis or episcleritis, deep venous thrombosis, cerebrovascular accident)
Patients with a history of arterial or venous thrombosis
Patients with history of deep venous thrombus or pulmonary embolism. Patients who are at increased risk of thrombosis during treatment with lenalidomide including those taking concurrent erythropoietin, darbepoetin or high-dose corticosteroids are also excluded.
History of venous or arterial thrombosis within the preceding year of enrollment
Have had DVT or venous thromboembolism within 6 weeks of study entry
Patients with a history of idiopathic deep venous thrombosis, pulmonary embolus, thrombotic stroke, or arterial thrombosis will be excluded from study; patients with a history of a central venous catheter-associated thrombosis that has completely resolved will be eligible for study but should be monitored for thrombosis
Patients at high-risk for thromboembolic disease, such as those with prior heterotopic ossification (h/o) deep venous thrombosis (DVT).
Patients with history of clinically significant venous thromboembolism
Patients with a history of clinically significant venous thromboembolism will be excluded
Patients with a history of venous or arterial thrombosis personally before the age of 40 years unless associated with a central line
Has had a symptomatic venous thrombosis within the 14 days prior to study enrollment - NOTE: Subjects with a history of a deep vein thrombosis 14 days prior to study enrollment who are on anticoagulation therapy with low molecular weight heparin are eligible for this study
They have a history of a venous or arterial thrombosis that was not associated to a central line.
The patient has a history of deep vein thrombosis (DVT), pulmonary embolism (PE), or any other significant thromboembolism (venous port or catheter thrombosis or superficial venous thrombosis are not considered \significant\) during the 3 months prior to first dose of protocol therapy
Patient must have no history of venous thrombosis within 12 weeks of randomization
History of clinically significant hemorrhagic or thrombotic event within the past 6 months, not including uncomplicated catheter-associated venous thrombosis; patients on anti-coagulation are not permitted to be on any oral formulations (warfarin, rivaroxaban, dabigatran, etc.) due to concern for drug-drug interaction
History of untreated deep venous thrombosis
have a history of deep venous thrombosis/embolism and who are not willing/able to take venous thromboembolic event prophylaxis during the entire treatment period
Have a history of arterial or venous embolism within 6 months prior to study entry.
Surgical arterial-portal venous shunt or arterial-venous shunt
Have a history of deep vein thrombosis, pulmonary embolism, or any other significant venous thromboembolism (venous catheter thrombosis or superficial venous thrombosis not considered \significant\) during the 3 months prior to study enrollment. Participants with venous thromboembolism occurring 3 to 6 months prior to study enrollment are allowed, if being treated with low molecular weight heparin.
History of deep venous thrombosis or migratory thrombophlebitis (Trousseau)
Subjects who are unwilling to take venous thromboembolism (VTE) prophylaxis
The participant has a history of arterial thromboembolism event (ATE) or venous thromboembolism event (VTE) within 3 months prior to study enrollment. Participants with history of VTE beyond 3 months prior to study enrollment can be enrolled if they are appropriately treated with low molecular weight heparin.
History of recurrent thrombosis or any thrombosis within the past 6 months
Has a history of arterial thromboembolism within 12 months of start of study drug
Patients with a history of deep venous thromboembolism or pulmonary embolism on treatment with anticoagulation are eligible for the study
History of arterial thrombosis (i.e. stroke) in the past year
History of venous thrombosis currently requiring anti-coagulation therapy
The patient has a known history of stroke, myocardial infarction, peripheral vascular disease, or recent (within 3 months) uncontrolled deep venous thrombosis.
PART B: Any history of venous or arterial thrombo-embolism, or previous revascularization procedure
History of arterial thrombosis (i.e. stroke) in the past year
History of venous thrombosis currently requiring anti-coagulation therapy
The ability to take aspirin or other appropriate venous thromboembolism (VTE) prophylaxis
History of venous or arterial thromboembolism within 12 months prior to enrollment/randomization
Patients with history of deep venous thrombus or pulmonary embolism; patients who are at increased risk of thrombosis during treatment with Revlimid including those taking concurrent erythropoietin, darbepoetin or high-dose corticosteroids are also excluded
Patients must not have had a deep venous or arterial thrombosis (non-central venous catheter related) within the last three months prior to study entry
Patients known or suspected to have hypercoagulable syndrome or with history of venous or arterial thrombosis, stroke, transient ischemic attack (TIA), or pulmonary embolism
Documented deep vein thrombosis within 1 year before enrollment on the study, except if upper arm thrombosis related to central venous catheters, within 3 months before enrollment on the study
History of deep venous or arterial thrombotic disease (including but not limited to, acute myocardial infarction due to coronary thrombosis, ischemic stroke, and peripheral arterial disease), unless:\r\n* Line-related thrombosis without embolus\r\n* Occurring >= 1 year prior to screening
Venous thromboembolism within one year
Venous thromboembolism within one year
Patients with a history of deep venous thrombosis, pulmonary embolism, and/or cerebrovascular accident or currently requiring systemic anticoagulation are eligible provided they are determined to be candidates for radical prostatectomy
History of arterial or venous embolism within 3 months prior to study enrollment. If the embolism occurred >3 and <6 months, the participant is eligible provided appropriate treatment according to institutional standard of care is ensured.
Significant or active cardiovascular disease, specifically including but not restricted to:\r\n* History of myocardial infarction \r\n* History of atrial or ventricular arrhythmia\r\n* Unstable angina within 6 months prior to first dose of ponatinib\r\n* History of congestive heart failure \r\n* Left ventricular ejection fraction (LVEF) less than lower limit of normal \r\n* History of peripheral arterial occlusive disease \r\n* History of cerebrovascular accident or transient ischemic attack \r\n* Venous thromboembolism including deep venous thrombosis or pulmonary embolism within 6 months prior to enrollment
History of arterial or deep venous thromboembolism within the 12 months prior to enrollment
Documented deep venous thrombosis
Clinical evidence of severe peripheral vascular disease, diabetic ulcers or venous stasis ulcers, or history of deep venous or arterial thrombosis within 3 months prior to screening
Patients with a history of venous or arterial thrombosis personally or in a first degree relative before the age of 40 years are not eligible unless the thrombotic event was associated with a central line.
Known arterial or venous thrombosis or pulmonary embolism within 2 years
History of venous or arterial thromboembolism within 12 months prior to enrollment/randomization
Patients with a history of clinically significant venous thromboembolism will be excluded on cohort 2; patients with tumor associated thrombus in the renal vein will not be excluded
DONOR: No other medical contraindications to stem cell donation (i.e. severe atherosclerosis, autoimmune disease, iritis or episcleritis, deep venous thrombosis, cerebrovascular accident); patients with a history of coronary artery bypass grafting or angioplasty will receive a cardiology evaluation and be considered on a case-by-case basis
Absolute contraindications: venous injury at the level of the femoral veins or proximally; known or suspected thrombosis of the femoral or iliac veins on the proposed side of venous cannulation, ambulatory patient
Patients with a history of the arterial or venous thromboembolism within =< 12 months of study entry are not eligible
History of arterial or venous thrombosis (excluding line-thrombosis) within the last 1 year, or those with known inherited coagulopathies; arterial or venous thrombosis includes pulmonary embolism, deep vein thrombosis of both upper (excluding line-thrombosis) and lower extremities, coronary artery disease managed medically or requiring intervention (percutaneous stent placement or coronary bypass surgery), cerebrovascular accident (for transient ischemic attacks clinical documentation is required), or involvement of other organs (such as hepatic, renal, spleen or other sites)
Arterial or venous thrombosis in the last year except for line-related venous thrombosis more than 3 months ago
Separate episode of VTE or arterial thrombosis within 3 months of enrollment
History of a deep venous thrombosis or a thromboembolism
Patients with a history of a prior symptomatic venous thrombotic event, such as deep venous thrombosis (DVT) or pulmonary embolism and symptomatic arterial thrombotic events such as myocardial infarction, ischemic cerebral vascular accident or transient ischemic attack will be ineligible if they have not tolerated anticoagulation therapy; if patients remain on anticoagulation, or have completed the prescribed course of anticoagulation, they will be eligible for enrollment; a venous thrombotic event associated with a central venous catheter will not make the patient ineligible
Patients with existing deep venous thrombosis will be excluded
Medical conditions:\r\n* Have a predisposition to or prior history of thromboembolism, deep venous thrombosis, pulmonary embolism, or stroke\r\n* History of renal or liver disease\r\n* Prior ovarian or endometrial cancer\r\n* Stopped or started hormone replacement within 8 weeks\r\n* Any other condition or intercurrent illness that in the opinion of the investigator makes the woman a poor candidate for RPFNA.
Arterial or venous thrombosis requiring active anticoagulation; (if a patient has a history of arterial or venous thrombosis and has completed anticoagulation therapy, then he/she is not excluded)
Patients who have a history of venous or arterial thromboembolic events including pulmonary embolism, deep venous thrombosis and stroke
Subjects with stroke, arterial or venous thrombosis within 6 months not eligible
Active deep venous thrombosis, pulmonary embolism, retinal vascular thrombosis, and any arterial thrombosis including stroke and myocardial infarction or history of these conditions